How we forecast tomorrow's haemovigilance

被引：1
|
作者：
Wood, Erica M. [1 ,2 ,6 ]
Whitaker, Barbee, I [3 ]
Townsend, Mary [4 ]
Narayan, Shruthi [5 ]
机构：
[1] Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 3004, Australia
[2] Monash Hlth, Dept Clin Haematol, Clayton Rd, Clayton, Vic 3168, Australia
[3] US FDA, Ctr Biol Evaluat & Res, Off Biostat & Pharmacovigilance, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[4] Vitalant, 9503 E Via Ventura, Scottsdale, AZ 85259 USA
[5] Manchester Blood Ctr, Serious Hazards Transfus SHOT, NHS Blood & Transplant, Manchester M13 9LL, England
[6] Monash Univ, 553 St Kilda Rd, Melbourne, Vic 3004, Australia
来源：
TRANSFUSION CLINIQUE ET BIOLOGIQUE | 2024年 / 31卷 / 02期
关键词：
Blood transfusion; Haemovigilance; Adverse reactions; Patient safety;
D O I：
10.1016/j.tracli.2024.03.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The field of haemovigilance continues to develop, building on more than forty years of international experience. This review considers the current scope and activities of haemovigilance around the world and explores aspects of preparation for the advent of new blood products and alternative therapies to transfusion; new tools for data acquisition (including patient- and donor-reported outcomes, and data from 'wearables') and the analysis and communication of haemovigilance results. (c) 2024 Soci & eacute;t & eacute; fran & ccedil;aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码：114 / 118
页数：5
相关论文
共 50 条
12345